Cirisano F - Search Results

1

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Among authors: cirisano f. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

2

Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.

Clifford SL, Kaminetsky CP, Cirisano FD, Dodge R, Soper JT, Clarke-Pearson DL, Berchuck A. Clifford SL, et al. Among authors: cirisano fd. Am J Obstet Gynecol. 1997 Jun;176(6):S229-32. doi: 10.1016/s0002-9378(97)70380-6. Am J Obstet Gynecol. 1997. PMID: 9215213

3

Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.

Elbendary AA, Cirisano FD, Evans AC Jr, Davis PL, Iglehart JD, Marks JR, Berchuck A. Elbendary AA, et al. Among authors: cirisano fd. Clin Cancer Res. 1996 Sep;2(9):1571-5. Clin Cancer Res. 1996. PMID: 9816335

4

Cell cycle control of BRCA2.

Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Vaughn JP, et al. Among authors: cirisano fd. Cancer Res. 1996 Oct 15;56(20):4590-4. Cancer Res. 1996. PMID: 8840967

5

BRCA2 monoclonal antibodies react with differentiating epithelium.

Gilliam LK, Lobenhofer EK, Greer PK, Scearce RM, Cirisano FD, Marks JR, Hale LP. Gilliam LK, et al. Hybrid Hybridomics. 2002 Aug;21(4):261-9. doi: 10.1089/153685902760213877. Hybrid Hybridomics. 2002. PMID: 12193279

6

The role of the HER-2/neu oncogene in gynecologic cancers.

Cirisano FD, Karlan BY. Cirisano FD, et al. J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. J Soc Gynecol Investig. 1996. PMID: 8796816 Review.

7

What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995?

Casey AC, Farias-Eisner R, Pisani AL, Cirisano FD, Kim YB, Muderspach L, Futoran R, Leuchter RS, Lagasse LD, Karlan BY. Casey AC, et al. Among authors: cirisano fd. Gynecol Oncol. 1996 Mar;60(3):454-61. doi: 10.1006/gyno.1996.0073. Gynecol Oncol. 1996. PMID: 8774657

8

Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation.

Karlan BY, Baldwin RL, Cirisano FD, Mamula PW, Jones J, Lagasse LD. Karlan BY, et al. Among authors: cirisano fd. Gynecol Oncol. 1995 Oct;59(1):67-74. doi: 10.1006/gyno.1995.1269. Gynecol Oncol. 1995. PMID: 7557618

9

Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. Cirisano FD Jr, et al. Gynecol Oncol. 1999 Sep;74(3):385-94. doi: 10.1006/gyno.1999.5505. Gynecol Oncol. 1999. PMID: 10479498

10

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. Cirisano FD Jr, et al. Gynecol Oncol. 2000 Apr;77(1):55-65. doi: 10.1006/gyno.2000.5737. Gynecol Oncol. 2000. PMID: 10739691

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters